408 Shares in argenx SE (NASDAQ:ARGX) Bought by West Family Investments Inc.

West Family Investments Inc. bought a new stake in argenx SE (NASDAQ:ARGX) during the fourth quarter, HoldingsChannel.com reports. The firm bought 408 shares of the company’s stock, valued at approximately $251,000.

Several other institutional investors have also recently bought and sold shares of the business. Steward Partners Investment Advisory LLC grew its holdings in shares of argenx by 5.6% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company’s stock valued at $234,000 after purchasing an additional 20 shares during the last quarter. SG Americas Securities LLC grew its stake in shares of argenx by 6.2% during the fourth quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock worth $220,000 after buying an additional 21 shares during the last quarter. Dynasty Wealth Management LLC grew its stake in shares of argenx by 3.4% during the fourth quarter. Dynasty Wealth Management LLC now owns 677 shares of the company’s stock worth $416,000 after buying an additional 22 shares during the last quarter. Choreo LLC increased its holdings in shares of argenx by 4.4% during the fourth quarter. Choreo LLC now owns 551 shares of the company’s stock worth $342,000 after buying an additional 23 shares in the last quarter. Finally, IFP Advisors Inc lifted its stake in shares of argenx by 4.2% in the 4th quarter. IFP Advisors Inc now owns 641 shares of the company’s stock valued at $394,000 after acquiring an additional 26 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on ARGX shares. Evercore ISI upped their target price on argenx from $675.00 to $706.00 and gave the stock an “outperform” rating in a report on Thursday, November 21st. Truist Financial reiterated a “buy” rating and issued a $700.00 price objective (up previously from $660.00) on shares of argenx in a report on Tuesday, January 14th. Wells Fargo & Company raised their price target on shares of argenx from $723.00 to $741.00 and gave the company an “overweight” rating in a research note on Friday, February 28th. Wolfe Research upgraded shares of argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 price target on the stock in a report on Tuesday, November 12th. Finally, Piper Sandler increased their price objective on argenx from $620.00 to $725.00 and gave the company an “overweight” rating in a report on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $662.83.

argenx Stock Performance

Shares of ARGX opened at $594.21 on Friday. The firm has a market cap of $36.10 billion, a PE ratio of -675.24 and a beta of 0.58. argenx SE has a 52-week low of $349.86 and a 52-week high of $678.21. The business’s 50 day moving average price is $642.09 and its two-hundred day moving average price is $593.03.

argenx (NASDAQ:ARGX) last issued its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.60. The business had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. Research analysts predict that argenx SE will post 3.13 EPS for the current fiscal year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.